Variables associated with outcomes after intermediate intensity dCBT
| Variables . | Value . | n . | Univariate analysis . | |
|---|---|---|---|---|
| HR (95% CI) . | P . | |||
| Neutrophil engraftment: dCBT recipients only (n = 47) | ||||
| TNC cell dose per kilogram | <2.6 × 107 | 21 | Reference | .286 |
| ≥2.6 × 107 | 26 | 1.38 (0.76-2.51) | ||
| TNC cell dose per kilogram | Continuous | 47 | 3.81 (1.31-11.01) | .014 |
| CD34+ cell dose per kilogram | <1.4 × 105 | 21 | Reference | .001 |
| ≥1.4 × 105 | 26 | 2.77 (1.51-5.09) | ||
| CD34+ cell dose per kilogram | Continuous | 47 | 2.53 (1.55-4.12) | <.001 |
| Donor-recipient 8-allele HLA-match | 3-4/8 | 20 | Reference | |
| 5/8 | 16 | 1.11 (0.56-2.19) | .764 | |
| 6-7/8 | 11 | 0.87 (0.41-1.86) | .723 | |
| Nonsignificant variables included engrafting unit CD3+ cell dose. Infused CD34+ dose represented viable cells. Haploidentical CD34+ cell recipients were excluded due to the transient engraftment of these cells in some patients. | ||||
| Grade III-IV aGVHD (n = 90) | ||||
| Nonsignificant variables included recipient age, sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, HCT-CI, rDRI and engrafting unit TNC, CD34+ and CD3+ cell doses, and 8-allele HLA match. | ||||
| TRM (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .03 |
| ≥50 | 42 | 4.19 (1.15-15.22) | ||
| Age, y | Continuous | 90 | 1.1 (1.0-1.20) | .016 |
| HCT-CI | 0-2 | 58 | Reference | .79 |
| 3-8 | 32 | 1.16 (0.38-3.56) | ||
| CD34+ cell dose per kilogram | <1.4 × 105 | 45 | Reference | .145 |
| ≥1.4 × 105 | 45 | 0.42 (0.13-1.35) | ||
| CD34+ cell dose per kilogram | Continuous | 90 | 0.30 (0.11-0.82) | .017 |
| Nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, rDRI and engrafting unit TNC, CD3+ cell doses, and 8-allele HLA-match. | ||||
| Relapse (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .261 |
| ≥50 | 42 | 0.46 (0.12-1.79) | ||
| Age, y | Continuous | 90 | 0.97 (0.92-1.03) | .330 |
| rDRI | Low-intermediate | 68 | Reference | .313 |
| High-very high | 22 | 1.92 (0.54-6.84) | ||
| Nonsignificant variables included recipient xer, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, HCT-CI and engrafting unit TNC and CD3+ cell doses, and 8-allele HLA match. | ||||
| OS (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .057 |
| ≥50 | 42 | 2.79 (0.97-8.03) | ||
| Age, y | Continuous | 90 | 1.09 (1.02-1.16) | .013 |
| HCT-CI | 0-2 | 58 | Reference | .446 |
| 3-8 | 32 | 1.47 (0.55-3.94) | ||
| CD34+ cell dose per kilogram | Continuous | 90 | 0.38 (0.14-0.99) | .047 |
| Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, rDRI and engrafting unit TNC and CD3+ cell doses, and 8-allele HLA match. | ||||
| PFS (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .364 |
| ≥50 | 42 | 1.47 (0.64-3.35) | ||
| Age, y | Continuous | 90 | 1.03 (0.98-1.07) | .218 |
| HCT-CI | 0-2 | 58 | Reference | .439 |
| 3-8 | 32 | 1.39 (0.61-3.16) | ||
| CD34+ cell dose per kilogram | Continuous | 90 | 0.57(0.26-1.27) | .171 |
| Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, rDRI and engrafting unit TNC and CD3+ cell doses, and 8-allele HLA match. | ||||
| Variables . | Value . | n . | Univariate analysis . | |
|---|---|---|---|---|
| HR (95% CI) . | P . | |||
| Neutrophil engraftment: dCBT recipients only (n = 47) | ||||
| TNC cell dose per kilogram | <2.6 × 107 | 21 | Reference | .286 |
| ≥2.6 × 107 | 26 | 1.38 (0.76-2.51) | ||
| TNC cell dose per kilogram | Continuous | 47 | 3.81 (1.31-11.01) | .014 |
| CD34+ cell dose per kilogram | <1.4 × 105 | 21 | Reference | .001 |
| ≥1.4 × 105 | 26 | 2.77 (1.51-5.09) | ||
| CD34+ cell dose per kilogram | Continuous | 47 | 2.53 (1.55-4.12) | <.001 |
| Donor-recipient 8-allele HLA-match | 3-4/8 | 20 | Reference | |
| 5/8 | 16 | 1.11 (0.56-2.19) | .764 | |
| 6-7/8 | 11 | 0.87 (0.41-1.86) | .723 | |
| Nonsignificant variables included engrafting unit CD3+ cell dose. Infused CD34+ dose represented viable cells. Haploidentical CD34+ cell recipients were excluded due to the transient engraftment of these cells in some patients. | ||||
| Grade III-IV aGVHD (n = 90) | ||||
| Nonsignificant variables included recipient age, sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, HCT-CI, rDRI and engrafting unit TNC, CD34+ and CD3+ cell doses, and 8-allele HLA match. | ||||
| TRM (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .03 |
| ≥50 | 42 | 4.19 (1.15-15.22) | ||
| Age, y | Continuous | 90 | 1.1 (1.0-1.20) | .016 |
| HCT-CI | 0-2 | 58 | Reference | .79 |
| 3-8 | 32 | 1.16 (0.38-3.56) | ||
| CD34+ cell dose per kilogram | <1.4 × 105 | 45 | Reference | .145 |
| ≥1.4 × 105 | 45 | 0.42 (0.13-1.35) | ||
| CD34+ cell dose per kilogram | Continuous | 90 | 0.30 (0.11-0.82) | .017 |
| Nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, rDRI and engrafting unit TNC, CD3+ cell doses, and 8-allele HLA-match. | ||||
| Relapse (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .261 |
| ≥50 | 42 | 0.46 (0.12-1.79) | ||
| Age, y | Continuous | 90 | 0.97 (0.92-1.03) | .330 |
| rDRI | Low-intermediate | 68 | Reference | .313 |
| High-very high | 22 | 1.92 (0.54-6.84) | ||
| Nonsignificant variables included recipient xer, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, HCT-CI and engrafting unit TNC and CD3+ cell doses, and 8-allele HLA match. | ||||
| OS (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .057 |
| ≥50 | 42 | 2.79 (0.97-8.03) | ||
| Age, y | Continuous | 90 | 1.09 (1.02-1.16) | .013 |
| HCT-CI | 0-2 | 58 | Reference | .446 |
| 3-8 | 32 | 1.47 (0.55-3.94) | ||
| CD34+ cell dose per kilogram | Continuous | 90 | 0.38 (0.14-0.99) | .047 |
| Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, rDRI and engrafting unit TNC and CD3+ cell doses, and 8-allele HLA match. | ||||
| PFS (n = 90) | ||||
| Age, y | <50 | 48 | Reference | .364 |
| ≥50 | 42 | 1.47 (0.64-3.35) | ||
| Age, y | Continuous | 90 | 1.03 (0.98-1.07) | .218 |
| HCT-CI | 0-2 | 58 | Reference | .439 |
| 3-8 | 32 | 1.39 (0.61-3.16) | ||
| CD34+ cell dose per kilogram | Continuous | 90 | 0.57(0.26-1.27) | .171 |
| Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34+ cells, rDRI and engrafting unit TNC and CD3+ cell doses, and 8-allele HLA match. | ||||
Infused cell dose and HLA-match variables are those of the engrafting unit. Infused TNC, infused viable CD34+, and infused viable CD3+ cell doses were naturally log transformed when examined as continuous variables because of skewness. Values of P < .05 are in bold.